MANNELLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.763
EU - Europa 4.079
AS - Asia 2.774
SA - Sud America 375
AF - Africa 59
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.097
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.719
RU - Federazione Russa 1.632
SG - Singapore 838
CN - Cina 776
IT - Italia 619
HK - Hong Kong 490
PL - Polonia 351
BR - Brasile 317
KR - Corea 287
DE - Germania 285
IE - Irlanda 272
SE - Svezia 260
FI - Finlandia 182
CH - Svizzera 149
VN - Vietnam 111
GB - Regno Unito 102
IN - India 81
FR - Francia 71
UA - Ucraina 63
AU - Australia 44
JO - Giordania 44
NL - Olanda 42
ID - Indonesia 36
TR - Turchia 26
CA - Canada 25
ES - Italia 21
AR - Argentina 18
BD - Bangladesh 18
CI - Costa d'Avorio 15
ZA - Sudafrica 14
EC - Ecuador 11
JP - Giappone 11
MA - Marocco 11
MX - Messico 11
IQ - Iraq 9
VE - Venezuela 8
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
BJ - Benin 5
CL - Cile 5
PY - Paraguay 5
AT - Austria 4
CO - Colombia 4
PH - Filippine 4
RO - Romania 4
SA - Arabia Saudita 4
EG - Egitto 3
KZ - Kazakistan 3
PE - Perù 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
AL - Albania 2
BE - Belgio 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
JM - Giamaica 2
KW - Kuwait 2
LT - Lituania 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PA - Panama 2
TN - Tunisia 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
OM - Oman 1
RS - Serbia 1
SD - Sudan 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TW - Taiwan 1
UG - Uganda 1
YT - Mayotte 1
Totale 13.097
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.570
Ashburn 605
Singapore 582
Fairfield 514
Hong Kong 421
Warsaw 349
Seoul 286
Chandler 283
Dublin 272
Woodbridge 231
Seattle 222
Hefei 214
Houston 195
Cambridge 187
Beijing 182
Munich 176
Wilmington 148
Bern 147
Florence 108
Buffalo 98
Altamura 96
Lawrence 96
Jacksonville 93
Ann Arbor 82
Helsinki 81
Princeton 76
Moscow 74
Los Angeles 67
New York 57
Dallas 56
Kent 50
Mumbai 46
Boston 44
Paris 43
Melbourne 42
Turku 42
Ho Chi Minh City 38
Medford 38
Shanghai 38
Boardman 37
San Diego 36
Milan 34
São Paulo 33
London 32
Jakarta 29
Bremen 28
Rome 25
Hanoi 22
Clifton 20
The Dalles 20
Lappeenranta 19
Abidjan 15
Redondo Beach 15
Brooklyn 13
Izmir 13
Rio de Janeiro 11
Tianjin 11
Bengaluru 10
Curitiba 10
Denver 10
Falls Church 10
Frankfurt am Main 10
Hillsboro 10
San Francisco 10
Siena 10
Yubileyny 10
Atlanta 9
Porto Alegre 9
Toronto 9
Chennai 8
Düsseldorf 8
Johannesburg 8
Norwalk 8
Phoenix 8
Sesto Fiorentino 8
Tokyo 8
Andover 7
Campinas 7
Chicago 7
Falkenstein 7
Haiphong 7
Manchester 7
Manresa 7
Montreal 7
Tashkent 7
Amsterdam 6
Dearborn 6
Fiesole 6
Pian di Scò 6
Poplar 6
Salerno 6
San Jose 6
Shenzhen 6
Washington 6
West Jordan 6
Casablanca 5
Cotonou 5
Genoa 5
Guangzhou 5
Mexico City 5
Totale 8.683
Salva come PNG Salva come JPEG
Nome #
CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. 291
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 287
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. 281
Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management 265
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 228
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 211
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 208
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 201
Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia 191
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial 190
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 184
A life-threatening ruxolitinib discontinuation syndrome 175
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 174
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 174
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 173
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 172
Progress in Italy in control and elimination of measles and congenital rubella. 171
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 170
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 170
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 169
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 167
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 164
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 163
Progress in Italy in control and elimination of measles and congenital rubella. 159
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML 158
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 155
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 155
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey 154
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 152
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. 152
Validation of the Mayo alliance prognostic system for mastocytosis 152
Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. 152
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. 151
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 151
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia 149
Implementation of the Plan for Elimination of Measles and Congenital Rubella Infection in Tuscany: evidence of progress towards phase II of measles control 147
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 146
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 144
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. 139
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 138
Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma 137
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 137
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial 136
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. 135
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. 135
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 134
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 131
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 130
Diagnostic and therapeutic challenges in mast cell sarcoma 129
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 128
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 128
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 127
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 125
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 124
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 123
Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models 121
SUBCUTANEOUS CAMPATH-1H IN REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: FEASIBILITY AND EFFICACY 120
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 120
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 119
Progress towards measles and rubella elimination in Tuscany,l Italy: the role of population seroepidemiological profile 119
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. 119
Diagnosis of a T-lineage acute Lymphoblastic leukemia through digitalized cell analysis of the pleural effusion 117
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 117
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 116
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 116
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. 115
Atypical acute leukemia early after liver transplantation. 114
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 114
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 113
Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. 113
Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. 112
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 112
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 111
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts 110
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 110
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 108
Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. 108
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 107
Implementazione del piano per l'eliminazione del morbillo e della rosolia congenita in Toscana: progressi verso la seconda fase di controllo dell'infezione. 103
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 102
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 101
Sieroepidemiologia della rosolia in Toscana: strategie di vaccinazione per il recupero dei suscettibili. 101
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series 101
High dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-Myl) in relapsed or refractory AML patients 97
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting 94
High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients. 91
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 90
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 88
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report 84
Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report 84
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases 83
High response rates and reduced first dose reactions with subcutaneous alemtuzumab in patients with relapsed and refractory CLL 81
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms 78
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 78
Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature 63
Totale 13.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021419 0 0 0 0 0 80 28 60 67 83 50 51
2021/2022520 17 38 48 14 32 26 23 49 32 15 95 131
2022/20231.512 118 278 94 95 92 225 159 77 135 19 44 176
2023/2024765 31 62 98 52 86 104 46 133 15 48 50 40
2024/20254.939 152 431 316 707 1.265 732 184 296 219 174 218 245
2025/20262.921 608 721 523 439 585 45 0 0 0 0 0 0
Totale 13.242